Potential trade-offs in treatment of premanifest Huntington's disease.
Identifieur interne : 000115 ( Main/Exploration ); précédent : 000114; suivant : 000116Potential trade-offs in treatment of premanifest Huntington's disease.
Auteurs : Roger L. Albin [États-Unis] ; James F. Burke [États-Unis]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
The potential long-term consequences of treatments delaying manifestations of neurodegenerative diseases have not been explored. Using Huntington disease (HD) data and Markov chain Monte Carlo methods, we simulated the effects of therapies with equivalent effects on time to onset of HD and survival with HD. Our results suggest substantial potential trade-offs in effects of these therapies; significant delays in time to onset of HD were accompanied by significant prolongations of survival after onset of HD. Under a variety of assumptions, treatments delaying onset of HD result in some patients likely to have a greater increase in survival with manifest HD compared to delays in time to onset of HD. Our results suggest that future work in HD should be sensitive to the potential existence of such trade-offs and that understanding the preferences of HD patients and the broader HD community will be increasingly important. Future research, trial design, and treatment strategies in HD and other mid-life-onset neurodegenerative disorders should consider the possibility of trade-offs in long-term consequences of disease-modifying treatments.
DOI: 10.1002/mds.26318
PubMed: 26173644
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000123
- to stream PubMed, to step Curation: 000123
- to stream PubMed, to step Checkpoint: 000115
- to stream Ncbi, to step Merge: 004395
- to stream Ncbi, to step Curation: 004395
- to stream Ncbi, to step Checkpoint: 004395
- to stream Main, to step Merge: 000115
- to stream Main, to step Curation: 000115
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential trade-offs in treatment of premanifest Huntington's disease.</title><author><name sortKey="Albin, Roger L" sort="Albin, Roger L" uniqKey="Albin R" first="Roger L" last="Albin">Roger L. Albin</name><affiliation wicri:level="2"><nlm:affiliation>Neurology Service & GRECC, VAAAHS, Ann Arbor, Michigan, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neurology Service & GRECC, VAAAHS, Ann Arbor, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Burke, James F" sort="Burke, James F" uniqKey="Burke J" first="James F" last="Burke">James F. Burke</name><affiliation wicri:level="2"><nlm:affiliation>Neurology Service & GRECC, VAAAHS, Ann Arbor, Michigan, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neurology Service & GRECC, VAAAHS, Ann Arbor, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26173644</idno><idno type="pmid">26173644</idno><idno type="doi">10.1002/mds.26318</idno><idno type="wicri:Area/PubMed/Corpus">000123</idno><idno type="wicri:Area/PubMed/Curation">000123</idno><idno type="wicri:Area/PubMed/Checkpoint">000115</idno><idno type="wicri:Area/Ncbi/Merge">004395</idno><idno type="wicri:Area/Ncbi/Curation">004395</idno><idno type="wicri:Area/Ncbi/Checkpoint">004395</idno><idno type="wicri:Area/Main/Merge">000115</idno><idno type="wicri:Area/Main/Curation">000115</idno><idno type="wicri:Area/Main/Exploration">000115</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potential trade-offs in treatment of premanifest Huntington's disease.</title><author><name sortKey="Albin, Roger L" sort="Albin, Roger L" uniqKey="Albin R" first="Roger L" last="Albin">Roger L. Albin</name><affiliation wicri:level="2"><nlm:affiliation>Neurology Service & GRECC, VAAAHS, Ann Arbor, Michigan, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neurology Service & GRECC, VAAAHS, Ann Arbor, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Burke, James F" sort="Burke, James F" uniqKey="Burke J" first="James F" last="Burke">James F. Burke</name><affiliation wicri:level="2"><nlm:affiliation>Neurology Service & GRECC, VAAAHS, Ann Arbor, Michigan, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neurology Service & GRECC, VAAAHS, Ann Arbor, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The potential long-term consequences of treatments delaying manifestations of neurodegenerative diseases have not been explored. Using Huntington disease (HD) data and Markov chain Monte Carlo methods, we simulated the effects of therapies with equivalent effects on time to onset of HD and survival with HD. Our results suggest substantial potential trade-offs in effects of these therapies; significant delays in time to onset of HD were accompanied by significant prolongations of survival after onset of HD. Under a variety of assumptions, treatments delaying onset of HD result in some patients likely to have a greater increase in survival with manifest HD compared to delays in time to onset of HD. Our results suggest that future work in HD should be sensitive to the potential existence of such trade-offs and that understanding the preferences of HD patients and the broader HD community will be increasingly important. Future research, trial design, and treatment strategies in HD and other mid-life-onset neurodegenerative disorders should consider the possibility of trade-offs in long-term consequences of disease-modifying treatments.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Albin, Roger L" sort="Albin, Roger L" uniqKey="Albin R" first="Roger L" last="Albin">Roger L. Albin</name></region><name sortKey="Burke, James F" sort="Burke, James F" uniqKey="Burke J" first="James F" last="Burke">James F. Burke</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000115 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000115 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26173644
|texte= Potential trade-offs in treatment of premanifest Huntington's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26173644" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |